WO2012098006A1 - Composés et procédés pour l'identification et la caractérisation de composés interagissant avec l'hdac - Google Patents

Composés et procédés pour l'identification et la caractérisation de composés interagissant avec l'hdac Download PDF

Info

Publication number
WO2012098006A1
WO2012098006A1 PCT/EP2012/000259 EP2012000259W WO2012098006A1 WO 2012098006 A1 WO2012098006 A1 WO 2012098006A1 EP 2012000259 W EP2012000259 W EP 2012000259W WO 2012098006 A1 WO2012098006 A1 WO 2012098006A1
Authority
WO
WIPO (PCT)
Prior art keywords
hdac
compound
ligand
binding
protein
Prior art date
Application number
PCT/EP2012/000259
Other languages
English (en)
Inventor
Nigel Ramsden
Valerie Reader
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag filed Critical Cellzome Ag
Priority to EP12700934.8A priority Critical patent/EP2665829A1/fr
Publication of WO2012098006A1 publication Critical patent/WO2012098006A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)

Definitions

  • the present invention relates to methods for the identification and characterization (e.g. selectivity profiling) of HDAC interacting compounds.
  • HDACs histone deacetylases
  • SAHA represents a non-selective HDAC inhibitor and is sometimes referred to as a "pan-HDAC” inhibitor.
  • the mechanisms underlying SAHA's anticancer activity are complex and not fully characterized.
  • the SAHA induces the accumulation of acetylated histones with an effect on gene expression.
  • non-histone proteins are substrates for HDACs and the effects on these proteins could contribute to its anticancer activities (Marks and Breslow, 2007. Nature Biotechnology 25(l):84-90; Grant et al., 2007. Nature Reviews Drug Discovery 6, 21-22).
  • HDACs catalyse the removal of acetyl groups from lysine residues in histone amino termini, leading to chromatin condensation and changes in gene expression.
  • HDACs In humans 18 HDACs have been identified and subdivided into four classes based on their homology to yeast HDACs, their subcellular localization and their enzymatic activities.
  • the class I HDACs (1, 2, 3 and 8) are homologous to the yeast RPD3 protein, can generally be detected in the nucleus and show ubiquitous expression in human cell lines and tissues.
  • Class II HDACs (4, 5, 6, 7, 9 and 10) are similar to the yeast Hda proteins and can shuttle between the nucleus and the cytoplasm.
  • HDAC6 can deacetylate the cytoskeletal protein a- tubulin.
  • HDAC1 1 is the sole member of class IV HDACs (Bolden et al., 2006. Nat. Rev. Drug Discov. 5(9):769-784).
  • Histone acetylation is a dynamic process controlled by HDACs and histone acetyltransferases (HATs) and the balance between these two processes together with other protein and DNA modifications such as DNA methylation regulates chromatin accessibility and gene expression.
  • HATs histone acetyltransferases
  • HDACs play a key role in developmental processes, normal physiology and disease states.
  • the ubiquitous expression and high homology between class I HDACs suggests functional redundancy among the HDACs in vivo.
  • deletion of each member of the class I HDAC family leads to lethality, indicating a unique role of each HDAC in development (Haberland et al., 2009. Nat. Rev. Genet. 10(l):32-42).
  • HDACs typically HDACs are present within multisubunit protein complexes together with other components that determine HDAC target gene specificity due to interactions with sequence-specific DNA-binding proteins (Cunliffe 2008. Curr. Opin. Genet. Dev. 18(5):404-410; Yang and Seto, 2008. Nat. Rev. Mol. Cell Biol. 9(3):206-218).
  • Class I HDACs are found primarily in four distinct multiprotein complexes known as the Sin3, NuRD, CoREST and NCoR/SMRT complexes.
  • the Sin3A complex contains as components HDAC1, HDAC2, RbAp46 (retinoblastoma (RB) associated protein-46) and RbAp48.
  • the complex contains RBPl (Rb-binding protein-1), SAP180 (which is similar to RBPl), SDS3, BRMS1 (breast cancer metastasis suppressor- 1, similar to SDS3), SAP30,SAP18 and ING1 (or ING2). Because some of the subunits have different isoforms, there are several distinct Sin3Acomplexes.
  • the Sin3B complex shares some similarity to the Sin3Acomplex but might also contain distinct subunits (Yang and Seto, 2008. Nat. Rev. Mol. Cell Biol. 9(3):206-218).
  • the nucleosome remodeling and deacetylase (NuRD) complex contains a catalytic core of HDAC 1 , HDAC2, RbAp46 and RbAp48.
  • this complex contains MTA (metastasis-associated) proteins, the nucleosome-remodelling ATPase Mi-2 (dermatomyositis-specific autoantigen), MBD2 (methyl CpG-binding domain-2) and p66.
  • MTA metalastasis-associated proteins
  • Mi-2 epidermatomyositis-specific autoantigen
  • MBD2 methyl CpG-binding domain-2
  • p66 methyl CpG-binding domain-2
  • the CoREST complex contains the corepressor protein CoREST interacting with the transcriptional repressor REST, HDAC1 and HDAC2. This complex is also referred to as neuronal corepressor complex because the REST zinc finger protein to target sites in the promoters of neuronal genes.
  • One subunit encodes the Lys-specific demethylase-1 (LSD1) protein which functions as a demethylase for K4-methylated histone H3.
  • LSD1 Lys-specific demethylase-1
  • the NCoR/SNRT complex contains the SANT-domain-containing co-repressors SMRT, NCoR and SMRTER and is targeted to DNA by transcription factor such as CSL and nuclear receptors.
  • HDAC inhibitors are in preclinical development and clinical trials for the treatment of a wide variety of diseases including cancer, inflammatory, cardiac, and neurodegenerative diseases (Bolden et al., 2006. Nat. Rev. Drug Discov. 5(9):769-784; Haberland et al., 2009. Nat. Rev. Genet. 10(l):32-42). It is expected that the development of selective HDAC inhibitors targeting only one member of the HDAC family should lead to improved efficacy and drug safety compared to non-selective "pan-HDAC inhibitors" (Kalin et al., 2009. Curr. Opin. Chem. Biol. 13: 1-9; Balasubramanian et al., 2009. Cancer Lett. 280(2):21 1-21).
  • HDAC activity can be measured using purified recombinant enzyme in solution-based assays with acetylated peptide substrates (Blackwell et al., 2008. Life Sciences 82(21-22): 1050-1058).
  • these assays require the availability of purified or recombinant HDACs. However, not all HDACs can be produced will sufficient enzymatic activity to allow for inhibitor screening (Blackwell et al., 2008. Life Sciences 82(21-22): 1050-1058). In addition, some preparations of HDACs expressed in insect cells are contaminated with endogenous insect HDACs making the interpretation of assay results ambiguous.
  • Another, although not in all instances necessary prerequisite for the identification of selective HDAC inhibitors is a method that allows to determine the target selectivity of these molecules. For example, it can be intended to provide molecules that bind to and inhibit a particular drug target but do not interact with a closely related target, inhibition of which could lead to unwanted side effects.
  • the present invention relates to a method for the identification of a histone deacetylase (HDAC) interacting compound, comprising the steps of a) providing an HDAC protein complex containing protein preparation derived from a cell endogenously expressing an HDAC, b) contacting the protein preparation with a given compound and with a ligand having the structure
  • the present invention relates to a method for the identification of a histone deacetylase (HDAC) interacting compound, comprising the steps of a) providing two aliquots of an HDAC protein complex containing protein preparation derived from a cell endogenously expressing an HDAC, b) contacting one aliquot with a ligand having the structure
  • R is H, C1-C6 alkyl, or cycloalkyl and X is a C1-C6 alkyl, cycloalkyl or an aryl, wherein the ligand is immobilized on a solid support via the NHR-group, thereby allowing the reversible binding of said ligand to said HDAC protein complex, c) contacting the other aliquot with a given compound and with the ligand as defined in step b), thereby allowing the reversible binding of said ligand to said HDAC protein complex, and d) determining to what extent in steps b) and c) a binding between the ligand and the protein complex has occurred.
  • the present invention relates to a method for the identification of a histone deacetylase (HDAC) interacting compound, comprising the steps of: a) providing two aliquots of a cell preparation each comprising at least one cell endogenously expressing an HDAC, b) incubating one aliquot with a given compound, c) harvesting the cells of each aliquot, lysing the cells of each aliquot in order to obtain protein preparations containing an HDAC protein complex, contacting the protein preparations with a ligand having the structure
  • R is H, C1 -C6 alkyl, or cycloalkyl and X is a C1-C6 alkyl, cycloalkyl or an aryl, wherein the ligand is immobilized on a solid support via the NHR-group, thereby allowing the reversible binding of said ligand to said HDAC protein complex, and f) determining to what extent in step e) a binding between the ligand and the
  • the present invention relates to a method for the identification of a histone deacetylase (HDAC) interacting compound, comprising the steps of a) providing at least two aliquots of an HDAC containing protein preparation derived from a cell endogenously expressing an HDAC, b) contacting one aliquot with a ligand as defined above thereby allowing the reversible binding of said ligand to HDAC, c) contacting the remaining aliquots with a ligand as defined above and with various concentrations of a compound thereby allowing the reversible binding of said ligand to HDAC, separating the HDAC from the the ligand, and e) determining by mass spectrometry or immunodetection the amount of HDAC eluted from the ligand, thereby determining to what extent in steps b) and c) a binding between the ligand and the protein has occurred.
  • HDAC histone deacetylase
  • the ligand as defined above is especially suitable for binding to HDACs, which enables its use in screening assays for the identification of HDAC interacting compounds. Especially, as shown in example 2 with the help of said compound and method of the invention, it is possible to identify HDAC proteins (for example HDAC2, HDAC6, HDAC 8 and HDAC 10).
  • the methods according to the first three aspects of the invention are especially suitable for the identification of a histone deacetylase (HDAC) interacting compound because they rely on the use of HDAC complexes which should ensure that the HDAC is present as much as possible in its natural environment.
  • the method according to the fourth aspect of the invention has been found especially suitable for the identification of a histone deacetylase (HDAC) interacting compound in that the binding characteristics of known HDAC inhibitors could be very well characterized using this method of the invention.
  • HDAC histone deacetylase
  • HDACs are:
  • HDAC1 Class I HDACs (HDAC1 , HDAC2, HDAC3, HDAC8);
  • HDAC4 HDAC5, HDAC7, HDAC9
  • HDAC6 HDAC 10
  • HDAC 1 class IV HDAC
  • HDAC2 HDAC2, HDAC6, HDAC8, and HDA10.
  • the expression "HDAC” relates to both human and other proteins of this family.
  • the expression especially includes functionally active derivatives thereof, or functionally active fragments thereof, or a homologues thereof, or variants encoded by a nucleic acid that hybridizes to the nucleic acid encoding said protein under low stringency conditions.
  • these low stringency conditions include hybridization in a buffer comprising 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% BSA, 100 ⁇ g/ml denatured salmon sperm DNA, and 10% (wt/vol) dextran sulfate for 18-20 hours at 40°C, washing in a buffer consisting of 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS for 1-5 hours at 55°C, and washing in a buffer consisting of 2X SSC, 25 mM Tris-HCl (pH 7.4) 5 mM EDTA, and 0.1% SDS for 1.5 hours at 60°C.
  • the expression "HDAC” includes mutant forms said HDACs.
  • first a protein preparation containing said HDAC (see the fourth aspect of the invention) or HDAC complex (see the first three aspects of the invention) is provided.
  • the methods of the present invention can be performed with any protein preparation as a starting material, as long as the respective HDAC or HDAC complex is present in the preparation and is derived from a cell endogenously expressing an HDAC.
  • Examples include a liquid mixture of several proteins, a cell lysate, a partial cell lysate which contains not all proteins present in the original cell or a combination of several cell lysates.
  • protein preparation also includes dissolved purified protein.
  • endogenously means that the respective cell expresses said HDAC without being transfected with an HDAC-encoding nucleic acid.
  • aliquots of a cell preparation are provided as the starting material.
  • the term "cell preparation” refers to any preparation containing at least one cell with the desired properties. Suitable cell preparations are described below.
  • the presence of the HDACs in a protein preparation of interest can be detected on Western blots probed with antibodies that are specifically directed against said HDAC. Alternatively, also mass spectrometry (MS) could be used to detect the HDACs (see below).
  • MS mass spectrometry
  • HDAC HDAC complexed to another known component of said complex.
  • Corresponding methods are well known in the art and include co- immunoprecipitation or purification of HDAC under conditions allowing that the HDAC complex is not dissociated.
  • Cell lysates or partial cell lysates can be obtained by isolating cell organelles (e.g. nucleus, mitochondria, ribosomes, golgi etc.) first and then preparing protein preparations derived from these organelles. Methods for the isolation of cell organelles are known in the art (Chapter 4.2 Purification of Organelles from Mammalian Cells in "Current Protocols in Protein Science", Editors: John.E. Coligan, Ben M. Dunn, Hidde L. Ploegh, David W. Speicher, Paul T. Wingfield; Wiley, ISBN: 0-471-14098-8).
  • cell organelles e.g. nucleus, mitochondria, ribosomes, golgi etc.
  • protein preparations can be prepared by fractionation of cell extracts thereby enriching specific types of proteins such as cytoplasmic or membrane proteins (Chapter 4.3 Subcellular Fractionation of Tissue Culture Cells in "Current Protocols in Protein Science", Editors: John.E. Coligan, Ben M. Dunn, Hidde L. Ploegh, David W. Speicher, Paul T. Wingfield; Wiley, ISBN: 0-471-14098-8).
  • protein preparations from body fluids can be used (e.g. blood, cerebrospinal fluid, peritoneal fluid and urine).
  • body fluids e.g. blood, cerebrospinal fluid, peritoneal fluid and urine.
  • whole embryo lysates derived from defined development stages or adult stages of model organisms such as C. elegans can be used.
  • whole organs such as heart dissected from mice can be the source of protein preparations. These organs can also be perfused in vitro in order to obtain a protein preparation.
  • the provision of a protein preparation includes the steps of harvesting at least one cell containing the HDAC or the HDAC protein complex and lysing the cell.
  • Suitable cells for this purpose as well as for the cell preparations used as the starting material in one aspect of the present invention are those cells or tissues where the HDACs are endogenously expressed. In any given cell or tissue only a subset of the HDACs may be expressed. Therefore it may be necessary to generate multiple protein preparations from a variety of cell types and tissues to cover the HDAC family, especially for selectivity profiling of HDAC inhibitors. As established cell lines may not reflect the physiological expression pattern of HDACs, primary animal or human cells may be used, for example cells isolated from blood samples. Therefore, in a preferred embodiment, cells isolated from peripheral blood represent a suitable biological material.
  • PBLs peripheral blood
  • W.E Biddison Chapter 2.2 "Preparation and culture of human lymphocytes” in Current Protocols in Cell Biology, 1998, John Wiley & Sons, Inc.
  • density gradient centrifugation is a method for the separation of lymphocytes from other blood cell populations (e.g. erythrocytes and granulocytes).
  • Human lymphocyte subpopulations can be isolated via their specific cell surface receptors which can be recognized by monoclonal antibodies.
  • the physical separation method involves coupling of these antibody reagents to magnetic beads which allow the enrichment of cells that are bound by these antibodies (positive selection).
  • primary human cells cultured cell lines e.g. MOLT-4 cells, Jurkat, Ramos, HeLa or K-562 cells
  • MOLT-4 cells e.g. MOLT-4 cells, Jurkat, Ramos, HeLa or K-562 cells
  • the cell is part of a cell culture system and methods for the harvest of a cell out of a cell culture system are known in the art (literature supra).
  • the choice of the cell will mainly depend on the expression of the HDACs, since it has to be ensured that the protein is principally present in the cell of choice.
  • methods like Westernblot, PCR-based nucleic acids detection methods, Northernblots and DNA- microarray methods ("DNA chips") might be suitable in order to determine whether a given protein of interest is present in the cell.
  • the choice of the cell may also be influenced by the purpose of the study. If the in vivo efficacy for a given drug needs to be analyzed then cells or tissues may be selected in which the desired therapeutic effect occurs (e.g. B-cells). By contrast, for the elucidation of protein targets mediating unwanted side effects the cell or tissue may be analysed in which the side effect is observed (e.g. cardiomyocytes, vascular smooth muscle or epithelium cells).
  • the cell containing the HDACs or the HDAC complex may be obtained from an organism, e.g. by biopsy.
  • a biopsy is a diagnostic procedure used to obtain a small amount of tissue, which can then be examined microscopically or with biochemical methods. Biopsies are important to diagnose, classify and stage a disease, but also to evaluate and monitor drug treatment. It is encompassed within the present invention that by the harvest of the at least one cell, the lysis is performed simultaneously. However, it is equally preferred that the cell is first harvested and then separately lysed.
  • Lysis of different cell types and tissues can be achieved by homogenizers (e.g. Potter-homogenizer), ultrasonic desintegrators, enzymatic lysis, detergents (e.g. NP-40, Triton ® X-100, CHAPS, SDS), osmotic shock, repeated freezing and thawing, or a combination of these methods.
  • homogenizers e.g. Potter-homogenizer
  • ultrasonic desintegrators e.g. Potter-homogenizer
  • enzymatic lysis e.g. NP-40, Triton ® X-100, CHAPS, SDS
  • detergents e.g. NP-40, Triton ® X-100, CHAPS, SDS
  • osmotic shock repeated freezing and thawing, or a combination of these methods.
  • the protein preparation containing the HDAC or the HDAC protein complex is contacted with a ligand as defined above thereby allowing the reversible binding of the HDAC complex or the HDAC to the ligand.
  • Alkyl means a straight-chain or branched saturated hydrocarbon chain. Each hydrogen of an alkyl carbon may be replaced by a substituent.
  • Ci -6 alkyl means an alkyl chain having 1 - 6 carbon atoms, e.g. if present at the end of a molecule: C alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert- butyl, n-pentyl, n-hexyl, or e.g.
  • Cycloalkyl means a cyclic alkyl chain having preferably 3 - 7 or 3 -5 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent.
  • Aryl means an aromatic ring system
  • Solid support relates to every undissolved support being able to immobilize a small molecule ligand on its surface.
  • the solid support may be selected from the group consisting of agarose, modified agarose, sepharose ® beads (e.g. NHS-activated sepharose ® ), latex, cellulose, and ferro- or ferrimagnetic particles.
  • the ligand has the structure
  • the ligand may further be labelled.
  • label is meant that the respective substance is either directly or indirectly labeled with a molecule which provides a detection signal, e.g. radioisotope, fluorescent tag, chemiluminescent tag, a peptide or specific binding molecules.
  • Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin.
  • the label can directly or indirectly provide a detectable signal.
  • the tag can also be a peptide which can be used, for example, in an enzyme fragment complementation assay (e.g. beta- galactosidase enzyme fragment complementation; Zaman et al., 2006. Assay Drug Dev. Technol. 4(4):41 1-420).
  • the labeled compounds would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for identifying kinase interacting compounds by inhibition of binding of the labeled compound, for example in kinase assays that contain such labeled compounds.
  • Radioisotopes are commonly used in biological applications for the detection of a variety of biomolecules and have proven to be useful in binding assays.
  • probes have been designed to incorporate H (also written as T for tritium) because it can replace hydrogen in a probe without altering its structure (Fenteany et al., 1995. Science 268:726-731).
  • An "isotopically" or “radio-labeled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
  • Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2 H (also written D for Deuterium), U C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 C1, 82 Br, 75 Br, 76 Br, 77 Br, 123 I, ,24 I, 125 I and 13 , I.
  • Guidance for the selection and methods for the attachment of fluorescent tags e.g.
  • fluorescein, rhodamine, dansyl, NBD (nitrobenz-2-oxa-l,3-diazole), BODIPY (dipyrromethene boron difluoride), and cyanine (Cy)-dyes) to small molecule ligands are generally known in the art (Vedvik et al., 2004. Assay Drug Dev. Technol. 2(2): 193-203; Zhang et al., 2005. Analytical Biochemistry 343(l):76-83).
  • fluorescent probes fluorophores
  • HTS high throughput screening
  • the change of the fluorescent properties after binding of the fluorescent probe to the target kinase can be determined by measuring for example fluorescence polarization (Kashem et al., 2007. J. Biomol. Screening 12(l):70-83), fluorescence resonance energy transfer (FRET; Zhang et al., 2005. Analytical Biochemistry 343(l):76-83) or fluorescence lifetime (Moger et al., 2006. J. Biomol. Screening 11(7): 765-772).
  • the ALPHAScreen technology can be used where the excitation of a donor bead at 680 nm produces singlet oxygen which can diffuse to an acceptor bead undergoing a chemi luminescent reaction (Glickman et al., 2002. J. Biomol. Screen. 7(1):3-10).
  • the ligand may be coupled to the solid support either covalently or non-covalently.
  • Non- covalent binding includes binding via biotin affinity ligands binding to steptavidin matrices.
  • the ligand is covalently coupled to the solid support.
  • the NHR-group may be modified accordingly if the ligand is covalently bound to the solid support.
  • Example 1 Methods for immobilizing compounds on solid supports are known in the art and further exemplified in Example 1.
  • the matrixes can contain active groups such as NHS, Carbodiimide etc. to enable the coupling reaction with the ligand.
  • the ligand can be coupled to the solid support by direct coupling (e.g. using functional groups such as amino-, sulfhydryl-, carboxyl-, hydroxyl-, aldehyde-, and ketone groups) and by indirect coupling (e.g. via biotin, biotin being covalently attached to the ligand and non-covalent binding of biotin to streptavidin which is bound directly to the solid support).
  • the linkage to the solid support material may involve cleavable and non-cleavable linkers. The cleavage may be achieved by enzymatic cleavage or treatment with suitable chemical methods.
  • the term "allowing the reversible binding” means that reversibly a complex is formed between the HDAC complex or the HDAC and the ligand.
  • Conditions allowing the reversible binding of molecules to proteins or protein complexes are known in the art. The skilled person will know which conditions can be applied in order to enable the formation of said complex.
  • the term "allowing the reversible binding” includes all conditions under which such binding is possible. This includes the possibility of having the solid support on an immobilized phase and pouring the lysate onto it. In another preferred embodiment, it is also included that the solid support is in a particulate form and mixed with the cell lysate. Such conditions are known to the person skilled in the art.
  • compounds are identified which interfere with the binding between the ligand and an HDAC or an HDAC protein complex present in a cell or protein preparation.
  • the binding between the ligand and the HDAC or the HDAC complex is, e.g., via salt bridges, hydrogen bonds, hydrophobic interactions or a combination thereof.
  • the steps of the formation of said complex are performed under essentially physiological conditions.
  • the physical state of proteins within cells is described in Petty, 1998 (Howard R. Petty, Chapter 1, Unit 1.5 in: Juan S. Bonifacino, Mary Dasso, Joe B. Harford, Jennifer Lippincott-Schwartz, and Kenneth M. Yamada (eds.) Current Protocols in Cell Biology Copyright ⁇ 2003 John Wiley & Sons, Inc. All rights reserved.
  • DPI 10.1002/0471 143030.cb0101 s00Online Posting Date: May, 2001Print Publication Date: October, 1998).
  • essentially physiological conditions are inter alia those conditions which are present in the original, unprocessed sample material. They include the physiological protein concentration, pH, salt concentration, buffer capacity and post-translational modifications of the proteins involved.
  • the term "essentially physiological conditions” does not require conditions identical to those in the original living organism, wherefrom the sample is derived, but essentially cell-like conditions or conditions close to cellular conditions. The person skilled in the art will, of course, realize that certain constraints may arise due to the experimental set-up which will eventually lead to less cell-like conditions.
  • the eventually necessary disruption of cell walls or cell membranes when taking and processing a sample from a living organism may require conditions which are not identical to the physiological conditions found in the organism.
  • Suitable variations of physiological conditions for practicing the methods of the invention will be apparent to those skilled in the art and are encompassed by the term "essentially physiological conditions” as used herein.
  • the term "essentially physiological conditions” relates to conditions close to physiological conditions, as e. g. found in natural cells, but does not necessarily require that these conditions are identical.
  • "essentially physiological conditions” may comprise 50-200 mM NaCl or KC1, pH 6.5-8.5, 20-37°C, and 0.001-10 mM divalent cation (e.g. Mg++, Ca++,); more preferably about 150 m NaCl or KC1, pH7.2 to 7.6, 5 mM divalent cation and often include 0.01-1.0 percent non-specific protein (e.g. BSA).
  • a non-ionic detergent can often be present, usually at about 0.001 to 2%, typically 0.05-0.2% (volume/volume).
  • buffered aequous conditions may be applicable: 10-250 mM NaCl, 5-50 mM Tris HC1, pH5-8, with optional addition of divalent cation(s) and/or metal chelators and/or non-ionic detergents.
  • "essentially physiological conditions" mean a pH of from 6.5 to 7.5, preferably from 7.0 to 7.5, and / or a buffer concentration of from 10 to 50 mM, preferably from 25 to 50 mM, and / or a concentration of monovalent salts (e.g. Na or ) of from 120 to 170 mM, preferably 150 mM.
  • Divalent salts e.g. Mg or Ca
  • the buffer is selected from the group consisting of Tris-HCl or HEPES.
  • washing is part of the knowledge of the person skilled in the art.
  • the washing serves to remove non-bound components of the cell lysate from the solid support.
  • Nonspecific (e.g. simple ionic) binding interactions can be minimized by adding low levels of detergent or by moderate adjustments to salt concentrations in the wash buffer.
  • the read-out system is whether a binding between the HDAC complex and the ligand (first three aspects of the invention) or whether a binding HDAC and the ligand (fourth aspect of the invention) has occurred.
  • Methods for determining whether a binding between a ligand and a protein or protein complex has occurred are known in the art. These methods include in situ methods where the binding is assessed without separating the protein or protein complex from the ligand.
  • anti-HDAC antibodies can be used in combination with the ALPHAScreen technology can be used where the excitation of a donor bead at 680 nm produces singlet oxygen which can diffuse to an acceptor bead undergoing a chemiluminescent reaction (Glickman et al., 2002. J. Biomol. Screen. 7(1):3-10).
  • the binding between the ligand and the HDAC complex or protein is determined by separating bound HDAC or HDAC complex from the ligand and subsequent determination of the HDAC or the HDAC complex.
  • This subsequent determination of the HDAC or HDAC complex may either be the detection of the HDAC or the HDAC complex in the eluate or the determination of their amount.
  • the fact that, in the methods of the invention, a binding between the HDAC ligand and the HDAC complex or the HDAC as occurred preferably indicates that the compound does not completely inhibit the binding.
  • the compound is presumably a strong interactor with the HDAC, which is indicative for its therapeutic potential.
  • the amount is determined, the less HDAC or HDAC complex can be detected in the eluate, the stronger the respective compound interacts with the HDAC, which is indicative for its therapeutic potential.
  • the extent of binding determined in step c) is indicative for the identification of a histone deacetylase (HDAC) interacting compound.
  • HDAC histone deacetylase
  • the extent of binding determined in step c) is compared to the extent of binding when steps a) to c) are performed in the absence of any compound. It is alternatively preferred that the extent of binding determined in step c) is compared to the extent of binding when steps a) to c) are performed in the presence of a different concentration of the given compound. In another preferred embodiment, a reduced extent of binding determined in step c) compared to the extent of binding determined in the absence of any compound, or equally preferred, compared to the extent of binding determined in the presence of the given compound at a lower concentration indicates that histone deacetylase (HDAC) is a target of the compound.
  • HDAC histone deacetylase
  • steps a) to c) are performed in parallel with different given compounds, preferably with at least two different compounds, more preferably with at least 5, 10, 100, 1000, 5000 or 10000 different compounds, or with any other number of compounds in between.
  • steps a) to c) are performed with different given compounds in the context of a high throughput screening assay.
  • the concentrations of the given compounds may either be similar or different to each other and may depend on the precise experimental set up of interest.
  • the concentration(s) of the given compound generally refer to any concentration of interest, including, but not limited to, concentrations calculated by either weight per volume, volume per volume, or molarity.
  • the method is performed by providing in step a) at least one further aliquot in addition (for example, a third, fourth, fifth or sixth aliquot etc.), and contacting and/or incubating this at least one further aliquot with the given compound, wherein the given compound has a different concentration than the concentration of the compound used in the previous aliquot.
  • the methods of the invention are performed by providing in step a) in addition at least one further aliquot (for example, a third, fourth, fifth, or sixth aliquot etc.), and contacting and/or incubating this at least one further aliquot with a given compound, wherein the given compound is different from the compound used in the previous aliquot.
  • a reduced binding observed for the aliquot incubated with the compound in comparison to the aliquot not incubated with the compound indicates that HDAC is a target of the compound
  • a reduced binding observed for the aliquot incubated with the compound at a higher concentration in comparison to the aliquot incubated with the compound at a lower concentration indicates that HDAC is a target of the compound.
  • separating means every action which destroys the interactions between the ligand and the HDAC or the HDAC protein complex.
  • This includes in a preferred embodiment the elution of the HDAC or the HDAC protein complex from the ligand.
  • the elution can be achieved by using non-specific reagents (ionic strength, pH value, detergents).
  • Such non-specific methods for destroying the interaction are principally known in the art and depend on the nature of the ligand enzyme interaction. Principally, change of ionic strength, the pH value, the temperature or incubation with detergents are suitable methods to dissociate the target enzymes from the immobilized compound.
  • the application of an elution buffer can dissociate binding partners by extremes of pH value (high or low pH; e.g. lowering pH by using 0.1 M citrate, pH2-3), change of ionic strength (e.g. high salt concentration using Nal, KI, MgCl 2 , or KC1), polarity reducing agents which disrupt hydrophobic interactions (e.g. dioxane or ethylene glycol), or denaturing agents (chaotropic salts or detergents such as Sodium-docedyl-sulfate, SDS; Review: Subramanian A., 2002, Immunoaffinty chromatography).
  • extremes of pH value high or low pH; e.g. lowering pH by
  • the solid support has preferably to be separated from the released material.
  • the individual methods for this depend on the nature of the solid support and are known in the art. If the support material is contained within a column the released material can be collected as column flowthrough. In case the support material is mixed with the lysate components (so called batch procedure) an additional separation step such as gentle centrifugation may be necessary and the released material is collected as supernatant.
  • magnetic beads can be used as solid support so that the beads can be eliminated from the sample by using a magnetic device.
  • the extent of the binding is determined by separating the HDAC protein complex from the ligand and subsequent detection of a component of the separated HDAC protein complex or subsequent determination of the amount of a component of the separated HDAC protein complex.
  • This preferred embodiment is especially advantageous, because it ensures that only HDAC protein complex is detected and not also free HDAC which has been bound to the ligand.
  • the component may be any component known to be part of the respective HDAC complex which binding to the ligand is to be assessed.
  • the detection of a component of the HDAC protein complex is especially suitable for identifying an HDAC interacting compound according to the methods of the invention. Consequently, in a preferred embodiment, the term "component of an HDAC protein complex" denotes a component of said complex which is not an HDAC protein.
  • an antibody in order to detect a respective protein (e.g. HDAC or a component of the HDAC complex), a specific antibody may be used (Wu and Olson, 2002. J. Clin. Invest. 109(10): 1327-1333). As indicated above, such antibodies are known in the art. Furthermore, the skilled person is aware of methods for producing the same.
  • mass spectrometry or immunodetection methods are used in the context of the methods of the invention.
  • the identification of proteins with mass spectrometric analysis is known in the art (Shevchenko et al., 1996, Analytical Chemistry 68: 850-858; Mann et al., 2001, Analysis of proteins and proteomes by mass spectrometry, Annual Review of Biochemistry 70, 437-473) and is further illustrated in the example section.
  • the mass spectrometry analysis is performed in a quantitative manner, for example by stable isotope labelling, to create a specific mass tag that can be recognized by a mass spectrometer and at the same time provide the basis for quantification.
  • mass tags can be introduced into proteins or peptides metabolically, by chemical means, enzymatically, or provided by spiked synthetic peptide standards (Bantscheff et al., 2007; Anal. Bioanal. Chem. 389(4): 1017-1031).
  • the mass spectrometry analysis is performed in a quantitative manner, for example by using iTRAQ ® technology (isobaric tags for relative and absolute quantification) or cICAT ® (cleavable isotope-coded affinity tags) (Wu et al., 2006. J. Proteome Res. 5, 651-658).
  • iTRAQ ® technology isobaric tags for relative and absolute quantification
  • cICAT ® cleavable isotope-coded affinity tags
  • tandem mass tag (TMT ® ) reagents can be used (commercially available from, e.g., Thermo Scientific).
  • tandem mass tag (TMT ® ) reagents are a set of multiplexed, amine-specific, stable isotope reagents that can label peptides in up to six different biological samples enabling simultaneous identification and quantitation of peptides.
  • the detection and/or the determination of binding between the ligand and the given compound is performed by quantitative mass spectrometry.
  • the characterization by mass spectrometry is performed by the identification of proteotypic peptides of the HDAC.
  • the idea is that the HDAC or the component of the HDAC complex is digested with proteases and the resulting peptides are determined by MS.
  • proteotypic peptide As a result, peptide frequencies for peptides from the same source protein differ by a great degree, the most frequently observed peptides that "typically" contribute to the identification of this protein being termed "proteotypic peptide”. Therefore, a proteotypic peptide as used in the present invention is an experimentally well observable peptide that uniquely identifies a specific protein or protein isoform.
  • the characterization is performed by comparing the proteotypic peptides obtained in the course of practicing the methods of the invention with known proteotypic peptides. Since, when using fragments prepared by protease digestion for the identification of a protein in MS, usually the same proteotypic peptides are observed for a given HDAC or component of the HDAC complex, it is possible to compare the proteotypic peptides obtained for a given sample with the proteotypic peptides already known for HDACs or the component and thereby identifying the HDAC or the component being present in the sample.
  • Suitable immunodetection methods include but are not limited to Western blots, ELISA assays, sandwich ELISA assays and antibody arrays or a combination thereof.
  • the establishment of such assays is known in the art (Chapter 1 1 , Immunology, pages 1 1-1 to 1 1 -30 in: Short Protocols in Molecular Biology. Fourth Edition, Edited by F.M. Ausubel et al., Wiley, New York, 1999).
  • These assays can not only be configured in a way to detect and quantify a HDAC interacting protein of interest, but also to analyse posttranslational modification patterns of HDAC or of other components of the HDAC protein complex such as phosphorylation or ubiquitin modification.
  • the identification methods of the invention involve the use of compounds which are tested for their ability to be a HDAC interacting compound.
  • such a compound can be every molecule which is able to interact with the HDAC, for example by inhibiting its binding to the Iigand.
  • the compound has an effect on the HDAC, e.g. a stimulatory or inhibitory effect.
  • said compound is selected from the group consisting of synthetic or naturally occurring chemical compounds or organic synthetic drugs, more preferably small molecule organic drugs or natural small molecule compounds.
  • Natural small molecules also referred to as natural products, are chemical compounds produced by a living organism found in nature that usually has a pharmacological or biological activity for use in pharmaceutical drug discovery and development (Cragg et al., 1997. J. Nat. Prod. 69, 52-60).
  • the compound has a molecular weight of less than 1000 Da.
  • said compound is identified starting from a library containing such compounds. Then, in the course of the present invention, such a library is screened.
  • small molecules are preferably not proteins or nucleic acids.
  • small molecules exhibit a molecular weight of less than 1000 Da, more preferred less than 750 Da, most preferred less than 500 Da.
  • a "library” relates to a (mostly large) collection of (numerous) different chemical entities that are provided in a sorted manner that enables both a fast functional analysis (screening) of the different individual entities, and at the same time provide for a rapid identification of the individual entities that form the library.
  • Examples are collections of tubes or wells or spots on surfaces that contain chemical compounds that can be added into reactions with one or more defined potentially interacting partners in a high-throughput fashion. After the identification of a desired "positive" interaction of both partners, the respective compound can be rapidly identified due to the library construction.
  • Libraries of synthetic and natural origins can either be purchased or designed by the skilled artisan.
  • Solid-phase chemistry is said to become an efficient tool for this optimisation process, and recent advances in this field are highlighted in this review article.
  • the current drug discovery processes in many pharmaceutical companies require large and growing collections of high quality lead structures for use in high throughput screening assays. Collections of small molecules with diverse structures and "drug-like" properties have, in the past, been acquired by several means: by archive of previous internal lead optimisation efforts, by purchase from compound vendors, and by union of separate collections following company mergers.
  • high throughput/combinatorial chemistry is described as being an important component in the process of new lead generation, the selection of library designs for synthesis and the subsequent design of library members has evolved to a new level of challenge and importance.
  • the potential benefits of screening multiple small molecule compound library designs against multiple biological targets offers substantial opportunity to discover new lead structures.
  • the HDAC or HDAC protein complex containing protein preparation is first incubated with the compound and then with the ligand.
  • the simultaneous incubation is equally preferred (competitive binding assay).
  • the HDAC or HDAC protein complex containing protein preparation is preferably first incubated with the compound for 10 to 60 minutes, more preferred 30 to 45 minutes at a temperature of 4°C to 37°C, more preferred 4°C to 25°C, most preferred 4°C.
  • Preferably compounds are used at concentrations ranging from 1 nM to 100 ⁇ , preferably from 10 nM to 10 ⁇ .
  • the second step, contacting with the ligand, is preferably performed for 10 to 60 minutes at 4°C.
  • the HDAC or HDAC protein complex containing protein preparation is preferably simultaneously incubated with the compound and the ligand for 30 to 120 minutes, more preferred 60 to 120 minutes at a temperature of 4°C to 37°C, more preferred 4°C to 25°C, most preferred 4°C.
  • compounds are used at concentrations ranging from 1 nM to 100 ⁇ , preferably from 10 nM to 10 ⁇ .
  • the methods of the invention may be performed with several protein preparations in order to test different compounds. This embodiment is especially interesting in the context of medium or high throughput screenings.
  • the identification methods of the invention are performed as a medium or high throughput screening.
  • the interaction compound identified according to the present invention may be further characterized by determining whether it has an effect on the HDAC, for example on its HDAC activity (Khan et al., 2008. Biochem. J. 409(2):581 -9; Blackwell et al., 2008. Life Sci. 82(21-22): 1050-1058).
  • the compounds identified according to the present invention may further be optimized (lead optimisation). This subsequent optimisation of such compounds is often accelerated because of the structure-activity relationship (SAR) information encoded in these lead generation libraries. Lead optimisation is often facilitated due to the ready applicability of high-throughput chemistry (HTC) methods for follow-up synthesis.
  • HTC high-throughput chemistry
  • the invention further relates to a method for the preparation of a pharmaceutical composition comprising the steps of a) identifying a HDAC interacting compound as described above, and b) formulating the interacting compound to a pharmaceutical composition.
  • the obtained pharmaceutical composition can be used for the prevention or treatment of diseases where the respective HDAC plays a role, e.g. for the prevention or treatment of cancer (Bolden et al., 2006. Nat. Rev. Drug Discov. 5(9):769-784).
  • HDAC inhibitors may be useful for the treatment of inflammatory diseases, cancer or neurodegenerative diseases.
  • the invention relates to a compound having the structure
  • R is H, C1-C6 alkyl or cycloalkyl and X is a C1-C6 alkyl, cycloalkyl or an aryl.
  • said compound of the invention has the structure
  • the invention further related to the use of the compound according of the invention for the capture and screening of HDAC, preferably of HDAC6, in protein complexes.
  • the compound is immobilized on a solid support via the NHR-group.
  • Figure 1 Synthesis of the compound of the invention. Steps: i) K 2 C0 3 , DMF, 80°C, ii) NaOHaq 4N, MeOH, iii) H2NOTHP, l -ethyl-3-(3-dimethylaminopropyl) carbodiimide, HOBT, N-methyl morpholine, DMF, iv4N HC1 in Dioxane. Methods used in the synthesis of the immobilization compound are described in example 1.
  • Figure 2 Structure of the preferred compound of the invention.
  • Figure 3 Amino acid sequence of human HDAC6 ( ⁇ 0000571 1.4). Peptides identified by mass spectrometry are underlined (K562; experiment X012865).
  • Figure 4 The percentage (%) of competition of proteins by 200 ⁇ bufexamac dissolved in DMSO is shown. Values have been normalized to 100 using the DMSO control sample as reference. The numbers above the bars indicate the number of quantified peptide spectra for each protein.
  • Coupling efficiency is determined by HPLC. Non- reacted NHS-groups were blocked by incubation with aminoethanol at room temperature on the end-over-end shaker over night. Beads were washed with 10 ml of DMSO and were stored in isopropanol at -20°C. These beads were used as the affinity matrix in the following examples. Control beads (no compound immobilized) were generated by blocking the NHS-groups by incubation with aminoethanol as described above.
  • Example 2 Bead experiment using an immobilized compound and K-562 cell lysate
  • This example demonstrates the use of an immobilized compound (structure shown in Figure 2) for the capturing and identification of proteins such as HDACs from cell lysate in a competition binding assay.
  • an immobilized compound structure shown in Figure 2 for the capturing and identification of proteins such as HDACs from cell lysate in a competition binding assay.
  • Beads were separated from the lysate and bead bound proteins were eluted in SDS sample buffer and subsequently separated by SDS-Polyacrylamide gel electrophoresis. Suitable gel bands were cut out and subjected to in-gel proteolytic digestion with trypsin. The second lysate aliquot was processed identically, however no bufexamac was added (DMSO solvent control).
  • the identified proteins are shown in Table 4 and Figure 4 including the percent competition values for the sample to which 200 ⁇ bufexamac was added. In total 4 different HDACs were identified. For illustration, the identified peptides for HDAC6 are shown in Figure 3. Sequence identifiers are defined by the International Protein Index (IPI) (Kersey et al., 2004. Proteomics 4(7): 1985-1988). 1. Cell culture
  • K-562 cell lysate was used (Bantscheff et al., 2007. Nature Biotechnology 25, 1035-1044).
  • K-562 cells (American Type Culture Collection-No. CCL-243) were either obtained from an external supplier (CIL SA, Mons, Belgium) or grown in one litre Spinner flasks (Integra Biosciences, #182101) in suspension in RPMI 1640 medium (Invitrogen, #21875-034) supplemented with 10% Fetal Bovine Serum (Invitrogen, #10270-106). Cells were harvested by centrifugation, washed once with 1 x PBS buffer (Invitrogen, #14190-094) and cell pellets were frozen in liquid nitrogen and subsequently stored at -80°C.
  • the material was dounced 20 times using a mechanized POTTER S, transferred to 50 ml falcon tubes, incubated for 30 minutes rotating at 4° C and spun down for 10 minutes at 20,000 x g at 4°C (10,000 rpm in Sorvall SLA600, precooled). The supernatant was transferred to an ultracentrifuge (UZ)- polycarbonate tube (Beckmann, 355654) and spun for 1 hour at 145.000 x g at 4°C (40.000 rpm in ⁇ 50.2, precooled). The supernatant was transferred again to a fresh 50 ml falcon tube, the protein concentration was determined by a Bradford assay (BioRad) and samples containing 50 mg of protein per aliquot were prepared. The samples were immediately used for experiments or frozen in liquid nitrogen and stored frozen at -80°C.
  • Sepharose ® -beads with the immobilized compound were equilibrated in lysis buffer and incubated with a cell lysate sample containing 5 mg of protein on an end-over-end shaker (Roto Shake Genie, Scientific Industries Inc.) for 2 hours at 4°C. Beads were collected, transferred to Mobicol-columns (MoBiTech 10055) and washed with 10 ml lysis buffer containing 0.4% NP40 detergent, followed by 5 ml lysis buffer containing 0.2 % detergent. To elute bound proteins, 60 ⁇ 2x SDS sample buffer was added to the column.
  • Gel-separated proteins were digested in-gel essentially following a previously described procedure (Shevchenko et al., 1996, Anal. Chem. 68:850-858). Briefly, gel-separated proteins were excised from the gel using a clean scalpel, destained twice using 100 ⁇ 5mM triethyl ammonium bicarbonate buffer (TEAB; Sigma T7408) and 40% ethanol in water and dehydrated with absolute ethanol. Proteins were subsequently digested in-gel with porcine trypsin (Promega) at a protease concentration of 10 ng/ ⁇ in 5mM TEAB. Digestion was allowed to proceed for 4 hours at 37°C and the reaction was subsequently stopped using 5 ⁇ 5% formic acid.
  • TEAB triethyl ammonium bicarbonate buffer
  • peptide extracts of samples treated with 200 ⁇ of free compound 6 (bufexamac) and the solvent control (0.5% DMSO) were treated with different variants of the isobaric tagging reagent (iTRAQ® Reagents Multiplex Kit, part number 4352135, Applied
  • the iTRAQ® reagents are a set of multiplexed, amine-specific, stable isotope reagents that can label peptides on amino groups in up to four different biological samples enabling simultaneous identification and quantitation of peptides.
  • the iTRAQ® reagents were used according to instructions provided by the manufacturer. The samples were resuspended in 10 ⁇ 50 mM TEAB solution, pH 8.5 and 10 ⁇ ethanol were added. The iTRAQ® reagent was dissolved in 120 ⁇ ethanol and 10 ⁇ of reagent solution were added to the sample.
  • the labeling reaction was performed at room temperature for one hour on a horizontal shaker and stopped by adding 5 ⁇ of 100 mM TEAB and 100 mM glycine in water. The two labeled sampled were then combined, dried in a vacuum centrifuge and resuspended in 10 ⁇ of 0.1% formic acid in water.
  • Peptide samples were injected into a nano LC system (CapLC, Waters or nano-LC 1D+, Eksigent) which was directly coupled either to a quadrupole TOF (QTOF Ultima, QTOF Micro, Waters), ion trap (LTQ) or Orbitrap mass spectrometer. Peptides were separated on the LC system using a gradient of aqueous and organic solvents (see below). Solvent A was 0.1% formic acid and solvent B was 70% acetonitrile in 0.1% formic acid.
  • the peptide mass and fragmentation data generated in the LC-MS/MS experiments were used to query a protein data base consisting of an in-house curated version of the International Protein Index (IPI) protein sequence database combined with a decoy version of this database (Elias and Gygi, 2007.
  • IPI International Protein Index
  • Proteins were identified by correlating the measured peptide mass and fragmentation data with data computed from the entries in the database using the software tool Mascot (Perkins et al., 1999. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567).
  • the 5x-DP buffer was filtered through a 0.22 ⁇ filter and stored in 40 ml-aliquots at -80°C.
  • Stock solutions were obtained from the following suppliers: 1.0 M Tris/HCl pH 7.5 (Sigma, T-2663), 87% Glycerol (Merck, catalogue number 04091.2500); 1.0 M MgCl 2 (Sigma, M-1028); 5.0 M NaCl (Sigma, S-5150).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés permettant l'identification de composés interagissant avec HDAC en utilisant le ligand ayant la structure dans laquelle R représente H, un C1-C6 alkyle, ou un cycloalkyle et X représente un C1-C6 alkyle, un cycloalkyle ou un aryle, le ligand étant immobilisé sur un support solide par le biais du groupe NHR ; elle concerne également des composés ayant lesdites structures.
PCT/EP2012/000259 2011-01-21 2012-01-20 Composés et procédés pour l'identification et la caractérisation de composés interagissant avec l'hdac WO2012098006A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12700934.8A EP2665829A1 (fr) 2011-01-21 2012-01-20 Composés et procédés pour l'identification et la caractérisation de composés interagissant avec l'hdac

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11000501.4 2011-01-21
EP11000501 2011-01-21

Publications (1)

Publication Number Publication Date
WO2012098006A1 true WO2012098006A1 (fr) 2012-07-26

Family

ID=43927988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/000259 WO2012098006A1 (fr) 2011-01-21 2012-01-20 Composés et procédés pour l'identification et la caractérisation de composés interagissant avec l'hdac

Country Status (2)

Country Link
EP (1) EP2665829A1 (fr)
WO (1) WO2012098006A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4018839A1 (fr) * 2020-12-23 2022-06-29 Red Bull GmbH Installation de fabrication d'une pluralité de récipients remplis de denrée alimentaire aqueuse et son utilisation ainsi que procédé de fabrication de denrées alimentaires aqueuses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001067107A1 (fr) * 2000-03-04 2001-09-13 Imperial College Innovations Limited Modulation de l'histone deacetylase
EP1582585A1 (fr) * 2002-12-27 2005-10-05 Astellas Pharma Inc. Procede de selection d'un nouvel immunosuppresseur
WO2006134056A1 (fr) 2005-06-14 2006-12-21 Cellzome Ag Procede d'identification de nouveaux composes interagissant avec les enzymes
WO2011018241A1 (fr) * 2009-08-14 2011-02-17 Cellzome Ag Procédés d’identification et de caractérisation de composés interagissant avec l’hdac

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001067107A1 (fr) * 2000-03-04 2001-09-13 Imperial College Innovations Limited Modulation de l'histone deacetylase
EP1582585A1 (fr) * 2002-12-27 2005-10-05 Astellas Pharma Inc. Procede de selection d'un nouvel immunosuppresseur
WO2006134056A1 (fr) 2005-06-14 2006-12-21 Cellzome Ag Procede d'identification de nouveaux composes interagissant avec les enzymes
WO2011018241A1 (fr) * 2009-08-14 2011-02-17 Cellzome Ag Procédés d’identification et de caractérisation de composés interagissant avec l’hdac

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Cell Biology", October 1998, JOHN WILEY & SONS, INC.
"Current Protocols in Protein Science", WILEY
"Sample Preparation Techniques in Analytical Chemistry", 2003, WILEY
"Short Protocols in Molecular Biology", 1999, WILEY
BALASUBRAMANIAN ET AL., CANCER LETT., vol. 280, no. 2, 2009, pages 211 - 21
BANTSCHEFF ET AL., ANAL. BIOANAL. CHEM., vol. 389, no. 4, 2007, pages 1017 - 1031
BANTSCHEFF ET AL., NATURE BIOTECHNOLOGY, vol. 25, 2007, pages 1035 - 1044
BANTSCHEFF M ET AL: "Revealing promiscuous drug-target interactions by chemical proteomics", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 14, no. 21-22, 1 November 2009 (2009-11-01), pages 1021 - 1029, XP026736595, ISSN: 1359-6446, [retrieved on 20090723], DOI: DOI:10.1016/J.DRUDIS.2009.07.001 *
BLACKWELL ET AL., LIFE SCI., vol. 82, no. 21-22, 2008, pages 1050 - 1058
BLACKWELL ET AL., LIFE SCIENCES, vol. 82, no. 21-22, 2008, pages 1050 - 1058
BOLDEN ET AL., NAT. REV. DRUG DISCOV., vol. 5, no. 9, 2006, pages 769 - 784
BREINBAUER R; MANGER M; SCHECK M; WALDMANN H: "Natural product guided compound library development", CURR. MED. CHEM., vol. 9, no. 23, 2002, pages 2129 - 2145
CRAGG ET AL., J. NAT. PROD., vol. 69, 1997, pages 52 - 60
CUNLIFFE, CURR. OPIN. GENET. DEV., vol. 18, no. 5, 2008, pages 404 - 410
ELIAS; GYGI: "Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry", NATURE METHODS, vol. 4, 2007, pages 207 - 214
ELIAS; GYGI: "Target-decoysearch strategy for increased confidence in large-scale protein identifications by mass spectrometry", NATURE METHODS, vol. 4, 2007, pages 207 - 214
FENTEANY ET AL., SCIENCE, vol. 268, 1995, pages 726 - 731
GLICKMAN ET AL., J. BIOMOL. SCREEN, vol. 7, no. 1, 2002, pages 3 - 10
GLICKMAN ET AL., J. BIOMOL. SCREEN., vol. 7, no. 1, 2002, pages 3 - 10
GRANT ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 6, 2007, pages 21 - 22
HABERLAND ET AL., NAT. REV. GENET., vol. 10, no. 1, 2009, pages 32 - 42
HAUSER ET AL., CURR. TOP. MED. CHEM., vol. 9, no. 3, 2009, pages 227 - 234
KALIN ET AL., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 1 - 9
KASHEM ET AL., J. BIOMOL. SCREENING, vol. 12, no. 1, 2007, pages 70 - 83
KERSEY ET AL., PROTEOMICS, vol. 4, no. 7, 2004, pages 1985 - 1988
KHAN ET AL., BIOCHEM. J., vol. 409, no. 2, 2008, pages 581 - 9
MANN ET AL., ANALYSIS OF PROTEINS AND PROTEOMES BY MASS SPECTROMETRY, ANNUAL REVIEW OF BIOCHEMISTRY, vol. 70, 2001, pages 437 - 473
MARKS; BRESLOW, NATURE BIOTECHNOLOGY, vol. 25, no. 1, 2007, pages 84 - 90
MOGER ET AL., J. BIOMOL. SCREENING, vol. 11, no. 7, 2006, pages 765 - 772
PERKINS ET AL.: "Probability-based protein identification by searching sequence databases using mass spectrometry data", ELECTROPHORESIS, vol. 20, 1999, pages 3551 - 3567, XP002319572, DOI: doi:10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2
REMISZEWSKI ET AL., J. MED. CHEM., vol. 46, no. 21, 2003, pages 4609 - 4624
RIESTER ET AL: "Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC, NEW YORK, vol. 362, no. 1, 1 March 2007 (2007-03-01), pages 136 - 141, XP022056712, ISSN: 0003-2697, DOI: DOI:10.1016/J.AB.2006.12.019 *
ROSS ET AL., MOL. CELL. PROTEOMICS, vol. 3, no. 12, 2004, pages 1154 - 1169
SALISBURY; CRAVATT, J. AM. CHEM. SOC., vol. 130, no. 7, 2008, pages 2184 - 2194
SALISBURY; CRAVATT, PNAS, vol. 104, no. 4, 2007, pages 1171 - 1176
SHEVCHENKO ET AL., ANAL. CHEM., vol. 68, 1996, pages 850 - 858
SHEVCHENKO ET AL., ANALYTICAL CHEMISTRY, vol. 68, 1996, pages 850 - 858
TROMMER ET AL., J. PHARM. PHARMACOL., vol. 55, no. 10, 2003, pages 1379 - 88
VEDVIK ET AL., ASSAY DRUG DEV. TECHNOL, vol. 2, no. 2, 2004, pages 193 - 203
W.E BIDDISON: "Current Protocols in Cell Biology", 1998, JOHN WILEY & SONS, INC., article "Preparation and culture of human lymphocytes"
WU ET AL., J. PROTEOME RES., vol. 5, 2006, pages 651 - 658
WU; OLSON, J. CLIN. INVEST., vol. 109, no. 10, 2002, pages 1327 - 1333
YANG; SETO, NAT. REV. MOL. CELL BIOL., vol. 9, no. 3, 2008, pages 206 - 218
ZAMAN ET AL., ASSAY DRUG DEV. TECHNOL., vol. 4, no. 4, 2006, pages 411 - 420
ZAMAN ET AL., COMB. CHEM. HIGH THROUGHPUT SCREEN, vol. 6, no. 4, 2003, pages 313 - 320
ZHANG ET AL., ANALYTICAL BIOCHEMISTRY, vol. 343, no. 1, 2005, pages 76 - 83

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4018839A1 (fr) * 2020-12-23 2022-06-29 Red Bull GmbH Installation de fabrication d'une pluralité de récipients remplis de denrée alimentaire aqueuse et son utilisation ainsi que procédé de fabrication de denrées alimentaires aqueuses

Also Published As

Publication number Publication date
EP2665829A1 (fr) 2013-11-27

Similar Documents

Publication Publication Date Title
EP2414337B1 (fr) Procédé d&#39;identification de molécules d&#39;interaction de kinase et de purification de protéines de kinase
Bao et al. Identification of ‘erasers’ for lysine crotonylated histone marks using a chemical proteomics approach
AU2007280631B2 (en) Methods for the identification of PI3K interacting molecules and for the purification of PI3K
Lenz et al. Probing small molecule–protein interactions: A new perspective for functional proteomics
AU2007224411B2 (en) Methods for the identification of LRRK2 interacting molecules and for the purification of LRRK2
EP2464967B1 (fr) Procédés pour l&#39;identification et la caractérisation des composés d&#39;interaction HDAC
Salisbury et al. Click Chemistry‐Led Advances in High Content Functional Proteomics
Nemmara et al. The development of benzimidazole-based clickable probes for the efficient labeling of cellular protein arginine deiminases (PADs)
WO2009098021A1 (fr) Détermination de profil de sélectivité de molécules interagissant avec la pi3k dirigées contre des cibles multiples
Ngubo et al. Nano-electrospray tandem mass spectrometric analysis of the acetylation state of histones H3 and H4 in stationary phase in Saccharomyces cerevisiae
Valente et al. Novel Cinnamyl Hydroxyamides and 2‐Aminoanilides as Histone Deacetylase Inhibitors: Apoptotic Induction and Cytodifferentiation Activity
Seidel et al. Peptide‐Based 2‐Aminophenylamide Probes for Targeting Endogenous Class I Histone Deacetylase Complexes
WO2012123119A1 (fr) Procédés d&#39;identification et de caractérisation de protéines interagissant avec des queues d&#39;histones et de composés interagissant avec lesdites protéines
WO2012098006A1 (fr) Composés et procédés pour l&#39;identification et la caractérisation de composés interagissant avec l&#39;hdac
EP2592154A1 (fr) Produits d&#39;immobilisation et procédés d&#39;identification de molécules d&#39;interaction de déméthylase d&#39;histone et de purification des protéines de déméthylase d&#39;histone
US20120135421A1 (en) Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins
Sharma et al. Multifunctional activity-based chemical probes for sirtuins
US20140004530A1 (en) Method for the evaluation of compound-target interactions across species
P Holly et al. Abundance-and activity-based proteomics in platelet biology
US20110070595A1 (en) Methods for the identification of parp interacting molecules and for purification of parp proteins
WO2012150042A1 (fr) Composés et procédés pour identifier des molécules ayant une interaction avec les histones déméthylases et pour purifier des protéines d&#39;histone déméthylase
EP2505659A1 (fr) Procédé d&#39;identification de molécules d&#39;interaction de dioxygénase et de purification de protéines de dioxygénase
Wolfson Determining HDAC8 Substrate Specificity.
Colzani et al. Proteomics-based drug discovery and chemoproteomics
Tallman et al. Measuring electrophile stress

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12700934

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012700934

Country of ref document: EP